Name (Synonyms) | Correlation | |
---|---|---|
drug2508 | SBRT Wiki | 0.45 |
drug869 | Device used to record voice for screening Wiki | 0.45 |
drug203 | Anatomic Pulmonary Resection Wiki | 0.45 |
drug3176 | anti-CD40 antibody Wiki | 0.45 |
drug1379 | IgG test Wiki | 0.45 |
drug949 | EHR-based Clinician Jumpstart Wiki | 0.45 |
drug2742 | Stereotactic Radiotherapy Wiki | 0.45 |
drug1074 | FLT3 Ligand Wiki | 0.45 |
drug757 | Convalescent Plasma Transfusion Wiki | 0.32 |
drug2360 | Radiation therapy Wiki | 0.32 |
drug1433 | Interferon Beta-1A Wiki | 0.22 |
drug812 | DAS181 Wiki | 0.18 |
drug1489 | Ivermectin Wiki | 0.10 |
drug1284 | Hydroxychloroquine Wiki | 0.09 |
drug2122 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D002289 | Carcinoma, Non-Small-Cell Lung NIH | 0.32 |
D016491 | Peripheral Vascular Diseases NIH | 0.32 |
D058729 | Peripheral Arterial Disease NIH | 0.26 |
D014652 | Vascular Diseases NIH | 0.26 |
D009362 | Neoplasm Metastasis NIH | 0.22 |
D008103 | Liver Cirrhosis, NIH | 0.22 |
D051437 | Renal Insufficiency, NIH | 0.20 |
D009369 | Neoplasms, NIH | 0.19 |
D007676 | Kidney Failure, Chronic NIH | 0.17 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.16 |
D006333 | Heart Failure NIH | 0.15 |
D017563 | Lung Diseases, Interstitial NIH | 0.13 |
D002908 | Chronic Disease NIH | 0.13 |
D008171 | Lung Diseases, NIH | 0.11 |
D003141 | Communicable Diseases NIH | 0.04 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100526 | Neoplasm of the lung HPO | 1.00 |
HP:0030358 | Non-small cell lung carcinoma HPO | 0.32 |
HP:0001395 | Hepatic fibrosis HPO | 0.22 |
HP:0004950 | Peripheral arterial stenosis HPO | 0.20 |
HP:0000083 | Renal insufficiency HPO | 0.20 |
HP:0002664 | Neoplasm HPO | 0.19 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.16 |
HP:0001635 | Congestive heart failure HPO | 0.15 |
HP:0006515 | Interstitial pneumonitis HPO | 0.13 |
HP:0002088 | Abnormal lung morphology HPO | 0.11 |
There are 5 clinical trials
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Description: Survival estimates will include death from any cause.
Measure: Overall Survival Time: From date of randomization through study completion, up to 10 yearsDescription: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Lung Cancer (LC 13) survey instruments will assess patients' general state of physical, social/family, emotional and functional well-being.
Measure: Patient reported health-related quality of life Time: 5 yearsDescription: The St George's Respiratory Questionnaire will evaluate respiratory symptoms, activity limitations from breathlessness, and impact of respiratory function on social and psychological functioning.
Measure: Respiratory Symptoms Time: 5 yearsDescription: The EQ-5D-5L (EuroQOL-5D) survey will measure quality adjusted life years.
Measure: Health State Utilities Time: 5 yearsDescription: Cause of death will be determined by an independent adjudication committee.
Measure: Lung cancer mortality Time: From date of randomization until date of death from any cause, assessed up to 10 years.Description: Post-treatment surveillance imaging will evaluate patients every 6 months for local, regional, and/or distant disease control.
Measure: Tumor patterns of failure Time: 5 yearsDescription: The Forced Expiratory Volume at 1 second (FEV1) will evaluate an objective measure of breathing function.
Measure: Respiratory Function Time: 5 yearsThe objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.
Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.
Measure: EHR documentation of Goals of Care discussions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU admissions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/Hospital use: Hospital length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: Hospital Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: ICU Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.
Measure: Intensity of care: Healthcare costs Time: 1 and 3 months after randomizationDescription: From Washington State death certificates.
Measure: All-cause mortality at 1 year (safety outcome) Time: 1 year after randomizationDescription: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.
Measure: Key Implementation Factors Time: 3 months after randomizationThis is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Measure: Clinical data of lung cancer patients with COVID-19 diagnoses Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Measure: Diagnosis data Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Measure: Treatments received Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Measure: Prognostic factors Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsObservational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
Measure: Description of the characteristics of patients Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeksThe purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.
Description: Death Any ≥ Grade 3 non-hematological toxicity, with the following exceptions: Grade 3 alopecia, vitiligo, or endocrinopathies controlled by hormone replacement therapy Grade 3 nausea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 vomiting and diarrhea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 fatigue that resolves to ≤ grade 2 within 5 days Grade 3 hypertension in the absence of maximal medical therapy Grade 3 adverse event of tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor) of ≤ 7 days in duration Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis. It is recommended to consult with the Principal Investigator for grade 4 amylase or lipase abnormalities Grade 3 clinically significant laboratory abnormalities that are asymptomatic and can be reversed within 72 hours, however: Any Grade 4
Measure: Phase I: Dose-limiting toxicity (DLT), defined as follows: Time: up to 8 weeks after initiation of study therapyDescription: Length of time that patient survives from time of study registration
Measure: Overall survival (OS) duration Time: From date of registration until the date of death from any cause, assessed up to 2 yearsDescription: The clinical benefit rate (CBR) will be defined as the percentage of subjects who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months.
Measure: Radiographic responses using descriptive statistics Time: From date of registration, assessed up to 4 monthsDescription: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. higher scores are a better level of functioning
Measure: Quality of Life using EORTC QLQ-LC13 (quality of Life Questionnaire, Lung Cancer) Time: 1 yearDescription: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. Most items are scored 1 to 4, higher scores are a better level of functioning.
Measure: Quality of Life using QLQ-C30 (Quality of Life Questionnaire) Time: 1 yearDescription: Average daily step counts
Measure: Daily step count using descriptive statistics Time: 1 year